EPM Packaging Inc - risultati della ricerca

Unione Europea - italiano - EMA (European Medicines Agency)

tepmetko

merck europe b.v. - tepotinib hydrochloride monohydrate - carcinoma, polmone non a piccole cellule - agenti antineoplastici - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

tepmetko 225 mg compresse rivestite con film

merck (schweiz) ag - tepotinibum - compresse rivestite con film - tepotinibum 225 mg ut tepotinibi hydrochloridum monohydricum 250 mg, mannitolum 455.33 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, lactosum monohydricum 4.37 mg, macrogola, triacetinum, e 171, e 172 (rubrum), pro compresso obducto. - behandlung von nicht-kleinzelligem lungenkarzinom mit met-alterationen - synthetika